|
Administration
May be taken with or without food.
|
|
Contraindications
Hypersensitivity. Active thromboembolic disease (e.g. pulmonary embolism, DVT), history of venous or arterial thrombosis (including retinal vein or artery occlusion), disseminated intravascular coagulation, fibrinolytic conditions after consumption coagulopathy, history of convulsions. Concomitant use with hormonal contraceptives. Severe renal impairment.
|
|
Special Precautions
Patients with enormous haematuria from upper urinary tract, history of thromboembolic diseases. Women with subarachnoid haemorrhage or irregular menstrual cycle. Mild to moderate renal impairment. Pregnancy and lactation. Patient Counselling This drug may cause dizziness, if affected, do not drive or operate machinery. Monitoring Parameters Perform eye examinations at baseline then regularly during treatment.
|
|
Adverse Reactions
Significant: Visual and ocular disturbance (e.g. impaired colour vision), retinal vein or artery occlusion, ligneous conjunctivitis, thromboembolic events, convulsions.
Blood and lymphatic system disorders: Anaemia.
Gastrointestinal disorders: Diarrhoea, nausea, vomiting, abdominal pain.
General disorders and administration site conditions: Fatigue.
Musculoskeletal and connective tissue disorders: Musculoskeletal pain, muscle cramps.
Nervous system disorders: Headache, migraine.
Respiratory, thoracic and mediastinal disorders: Nasal and sinus symptoms.
Potentially Fatal: Severe hypersensitivity reactions including anaphylaxis. |
|
Drug Interactions
Antagonistic effects with thrombolytics (e.g. alteplase, reteplase). Increased risk of thrombosis with factor IX complex concentrates or anti-inhibitor coagulant concentrates. May enhance the procoagulant effect of all-trans retinoic acid (oral tretinoin) in women with acute promyelocytic leukaemia.
|
|
CIMS Class
|
|
ATC Classification
B02AA02 - tranexamic acid ; Belongs to the class of amino acid antifibrinolytics. Used in the treatment of hemorrhage.
|
Sign Out
